DMAMCL induces ferroptosis in neuroblastoma by targeting HMOX1 in MYCN-amplified subtypes whereas targeting STEAP3 in MYCN-nonamplified subtypes.
Ma Yifan, Zhang Simeng, Zhang Dongyang, Hua Zhongyan, Li Zhijie
Abstract
OBJECTIVES: Neuroblastoma (NB) is a common pediatric extracranial solid tumor. Dimethylaminomicheliolide (DMAMCL), a prodrug of Micheliolide (MCL), shows antitumor activity against NB, but its mechanisms remain unclear. This study investigated the antitumor mechanisms of DMAMCL in NB. METHODS: Key pathways/genes were identified by RNA-seq and ferroptosis PCR array. Ferroptosis was confirmed by indicators. Mechanisms were investigated using siRNAs, shRNAs, and overexpression plasmids in vitro and in vivo. Direct targets were screened by LiP-MS. Molecular biology experiments elucidated the mechanisms. RESULTS: DMAMCL induced ferroptosis in NB in vitro and in vivo, upregulating HMOX1. HMOX1 knockdown attenuated DMAMCL-induced ferroptosis and its overexpression triggered ferroptosis in MYCN-amplified NB cells but not in MYCN-nonamplified cells. DMAMCL-induced ferroptosis via HMOX1 upregulation depended on MYCN levels. Mechanistically, DMAMCL bound to KEAP1 in MYCN-amplified NB cells, increasing nuclear NRF2 and upregulating HMOX1. In MYCN-nonamplified NB cells, DMAMCL upregulated STEAP3, increasing Fe2+ and lipid peroxidation to induce ferroptosis. STEAP3 overexpression induced ferroptosis and suppressed tumor growth. DISSCUSION: DMAMCL induces ferroptosis in NB through MYCN-associated dual pathways, activating the NRF2/HMOX1 axis via KEAP1 binding in MYCN-amplified cells, while upregulating STEAP3 in MYCN-nonamplified cells. This provides new insights for DMAMCL application in treating NB subtypes with different MYCN levels.
Key Findings
- DMAMCL induces ferroptosis in neuroblastoma cells both in vitro and in vivo.
- In MYCN-amplified neuroblastoma cells, DMAMCL binds to KEAP1, activates NRF2, and upregulates HMOX1 to trigger ferroptosis.
- In MYCN-nonamplified neuroblastoma cells, DMAMCL induces ferroptosis by upregulating STEAP3, which increases Fe2+ and lipid peroxidation.
Clinical Significance
This study identifies distinct NRF2-related ferroptosis pathways targeted by DMAMCL in neuroblastoma subtypes, suggesting tailored therapeutic strategies based on MYCN amplification status.
Citation
Ma Yifan, Zhang Simeng, Zhang Dongyanget al.. DMAMCL induces ferroptosis in neuroblastoma by targeting HMOX1 in MYCN-amplified subtypes whereas targeting STEAP3 in MYCN-nonamplified subtypes. Redox report : communications in free radical research. 2026-Dec-31.